Investigation of the Levels of Serum Amyloid A, <scp>YKL</scp>‐40, and Pentraxin‐3 in Patients with Familial Mediterranean Fever

Ciftci, Sefa; Çelik, Hüseyin; Atukeren, Pınar; Çiftçi, Nurdan; Deniz, Mustafa; Yavuz, Yasemin; Kazancı, Fatmanur Hacıevliyagil; Gok, Sumeyye; Demırın, Hilmi; Yiğitoğlu, M. Ramazan

doi:10.1002/jcla.21997

Cited by 8 publications

(9 citation statements)

References 27 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The elevation of this sensitive biomarker of inflammation in patients suffering from AV may indicate its participation in acne pathogenesis. This also was observed in other inflammatory diseases in which this inflammatory biomarker was studied, including rheumatoid arthritis, Behcet's disease, Familial Mediterranean fever and Alzheimer's disease . However, it has to be noted that the higher level of YKL‐40 may only reflect the level of systemic inflammation in AV patients, as its concentration does not relate with the severity of skin changes in the current study.…”

Section: Discussionsupporting

confidence: 57%

Serum YKL40: A novel potential link between inflammation and dyslipidemia in acne vulgaris

Ebrahim

Mustafa

El-Shimi

et al. 2019

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Acne vulgaris (AV) is an inflammatory skin disorder that may be associated with metabolic disorders. The relation between lipid profile in acne is not widely investigated. Chitinase‐3‐like protein 1 (YKL‐40) has been found to be implicated in different inflammatory conditions. Aims We aimed at investigating the role YKL‐40 in acne pathogenesis and associated dyslipidemia in acne patients. Patients/Methods This study included 50 acne vulgaris patients and 30 matched control subjects. Serum YKL‐40 in addition to lipid profile were assessed in all studied subjects. Results Serum YKL‐40 level was significantly elevated in acne patients than healthy controls (P < .001). We also found a significant positive correlations between serum YKL‐40, serum TGs, TC, and LDL‐C (P value: .022, .001, .017 respectively) while, a significant negative correlation between serum YKL‐40 and HDL‐c (P value: .036) was detected. Conclusion Our study results suggest that YKL‐40 might have a role in AV pathogenesis. In addition, it could provide a new potential link between inflammation and dyslipidemia observed in acne patients.

show abstract

Section: Discussionsupporting

confidence: 57%

Serum YKL40: A novel potential link between inflammation and dyslipidemia in acne vulgaris

Ebrahim

Mustafa

El-Shimi

et al. 2019

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…The association between SAA and RDs was reported in 32 studies (38 group comparators) evaluating a total of 2365 RD patients (mean age 44 years, 69% females) and 1632 healthy controls (mean age 43 years, 66% females) [ 41 – 72 ] (Table 1 ). Eighteen studies were conducted in Asia [ 41 , 42 , 44 – 46 , 48 , 50 , 55 , 57 , 59 – 61 , 65 – 69 , 72 ], six in Europe [ 52 – 54 , 58 , 62 , 64 ], five in America [ 47 , 49 , 51 , 56 , 70 ], two in Africa [ 63 , 71 ], and one in Oceania [ 43 ]. Thirteen study comparators included patients with RA [ 42 , 43 , 47 , 49 , 52 , 55 , 56 , 63 , 65 , 67 , 71 ], five with SLE [ 45 , 46 , 55 , 58 ], five with FMF [ 53 , 57 , 59 , 60 , 66 ], three with Takayasu arteritis (TA) [ 48 , 61 , 69 ], two with AS [ 44 , 68 ], two with SSc [ 54 , 62 ], two with osteoarthritis (OA) [ 52 , 55 ], one with BD [ 41 ], one with Henoch–Schönlein purpura (HSP) [ 50 ], one with spondylarthritis (SpA) [ 5...…”

Section: Resultsmentioning

confidence: 99%

“…Eighteen studies were conducted in Asia [ 41 , 42 , 44 – 46 , 48 , 50 , 55 , 57 , 59 – 61 , 65 – 69 , 72 ], six in Europe [ 52 – 54 , 58 , 62 , 64 ], five in America [ 47 , 49 , 51 , 56 , 70 ], two in Africa [ 63 , 71 ], and one in Oceania [ 43 ]. Thirteen study comparators included patients with RA [ 42 , 43 , 47 , 49 , 52 , 55 , 56 , 63 , 65 , 67 , 71 ], five with SLE [ 45 , 46 , 55 , 58 ], five with FMF [ 53 , 57 , 59 , 60 , 66 ], three with Takayasu arteritis (TA) [ 48 , 61 , 69 ], two with AS [ 44 , 68 ], two with SSc [ 54 , 62 ], two with osteoarthritis (OA) [ 52 , 55 ], one with BD [ 41 ], one with Henoch–Schönlein purpura (HSP) [ 50 ], one with spondylarthritis (SpA) [ 51 ], one with polymyalgia rheumatica (PMR) [ 64 ], one with PsA [ 70 ], and one with gout [ 72 ]. Mean RD duration was reported in 14 studies and ranged between 2.7 and 21.7 years [ 43 ...…”

Section: Resultsmentioning

confidence: 99%

The potential role of serum amyloid A as biomarker of rheumatic diseases: a systematic review and meta-analysis

Zinellu,

Mangoni

2024

Clin Exp Med

View full text Add to dashboard Cite

The identification of novel, robust biomarkers for the diagnosis of rheumatic diseases (RDs) and the presence of active disease might facilitate early treatment and the achievement of favourable long-term outcomes. We conducted a systematic review and meta-analysis of studies investigating the acute phase reactant, serum amyloid A (SAA), in RD patients and healthy controls to appraise its potential as diagnostic biomarker. We searched PubMed, Scopus, and Web of Science from inception to 10 April 2024 for relevant studies. We evaluated the risk of bias and the certainty of evidence using the JBI Critical Appraisal Checklist and GRADE, respectively (PROSPERO registration number: CRD42024537418). In 32 studies selected for analysis, SAA concentrations were significantly higher in RD patients compared to controls (SMD = 1.61, 95% CI 1.24–1.98, p < 0.001) and in RD patients with active disease compared to those in remission (SMD = 2.17, 95% CI 1.21–3.13, p < 0.001). Summary receiving characteristics curve analysis showed a good diagnostic accuracy of SAA for the presence of RDs (area under the curve = 0.81, 95% CI 0.78–0.84). The effect size of the differences in SAA concentrations between RD patients and controls was significantly associated with sex, body mass index, type of RD, and study country. Pending the conduct of prospective studies in different types of RDs, the results of this systematic review and meta-analysis suggest that SAA is a promising biomarker for the diagnosis of RDs and active disease.

show abstract

“…In this context, it is known that one of the pivotal inflammatory marker suitable for monitoring SAIDs progression and worsening is SAA (24). SAA is an acute phase reactant released into the circulation from the liver in response to infections or injuries and it is able to induce other pro-inflammatory cytokines and chemokines production (25). It is known that even during the asymptomatic attack-free periods, when the subclinical inflammation persists, SAA levels remain high in patients perpetuating possible systemic damages (26).…”

Section: Discussionmentioning

confidence: 99%

Osteoporosis in Systemic Autoinflammatory Diseases: A Case-Control Study

et al. 2019

View full text Add to dashboard Cite

Objective: To assess if patients affected by systemic autoinflammatory diseases (SAIDs) present an increased risk of osteoporosis (OP).Methods: Forty adults patients referred to the Rheumatology Unit of Padova University Hospital affected by Familial Mediterranean Fever (FMF), TNF-Receptor Associated Periodic Syndrome (TRAPS), and Mevalonate Kinase Deficiency (MKD) and 40 healthy subjects were enrolled. Blood and urine samples were collected in order to define phosphocalcic metabolism, including Receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG), and among inflammatory markers serum amyloid A (SAA). Femur and lumbar dual-energy X-ray absorptiometry (DXA) scans were performed and Trabecular Bone Score (TBS) was calculated on DXA lumbar images.Results: We did not observe a statistically significant difference between Bone Mineral Density (BMD) and TBS of patients compared to controls. Also, the values of phosphocalcic metabolites in patients did not statistically differ from those in controls. However, SAA and OPG levels were significantly higher in patients compared to healthy subjects (p = 0.0244 and p = 0.0064, respectively).Conclusion: Patients of our cohort affected by FMF, TRAPS, and MKD do not present an increased risk of OP compared to the healthy controls. TBS and BMD are similar between the two groups underlining a preserved bone quality in patients. High OPG levels could suggest a protective role and a bone re-balancing action in response to an inflammatory background. Finally, it should be taken into account a modulatory role played by a pro-inflammatory cytokine such as SAA on bone homeostasis.

show abstract

Investigation of the Levels of Serum Amyloid A, YKL‐40, and Pentraxin‐3 in Patients with Familial Mediterranean Fever

Abstract: YKL-40 can be used together with SAA to support the diagnosis of FMF and to monitor the severity of the disease. In this study, YKL-40 levels were examined for the first time in FMF patients and further studies are necessary using larger patient samples.

Cited by 8 publications

References 27 publications

Serum YKL40: A novel potential link between inflammation and dyslipidemia in acne vulgaris

Serum YKL40: A novel potential link between inflammation and dyslipidemia in acne vulgaris

The potential role of serum amyloid A as biomarker of rheumatic diseases: a systematic review and meta-analysis

Osteoporosis in Systemic Autoinflammatory Diseases: A Case-Control Study

Contact Info

Product

Resources

About